A novel Hsp70 inhibitor specifically targeting the cancer-related Hsp70-Bim protein-protein interaction

Eur J Med Chem. 2021 Aug 5:220:113452. doi: 10.1016/j.ejmech.2021.113452. Epub 2021 Apr 14.

Abstract

Targeting cancer-related Hsp70-Bim protein-protein interactions (PPIs) offers a new strategy for the design of Hsp70 inhibitors. Herein, we discovered a novel Hsp70 inhibitor, S1g-6, based on the established BH3 mimetics. S1g-6 exhibited sub-μM binding affinity toward Hsp70 and selectively disrupted Hsp70-Bim PPI. The target specificity of S1g-6in situ was validated by affinity-based protein profiling, co-immunoprecipitation, and cell-based shRNA assays. S1g-6 specifically antagonized the ATPase activity of Hsp70 upon recruiting Bim and showed selective apoptosis induction in some cancer cell lines over normal ones through suppression of some oncogenic clients of Hsp70, representing a new class of antitumor candidates. Hsp70-Bim PPI exhibited cancer-dependent role as a potential anti-cancer target.

Keywords: Antitumor candidate; Cancer-related target; Hsp70 inhibitor; Hsp70-bim PPI.

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Bcl-2-Like Protein 11 / antagonists & inhibitors*
  • Bcl-2-Like Protein 11 / chemistry
  • Dose-Response Relationship, Drug
  • HSP70 Heat-Shock Proteins / antagonists & inhibitors*
  • HSP70 Heat-Shock Proteins / chemistry
  • Humans
  • Molecular Structure
  • Protein Binding
  • Structure-Activity Relationship

Substances

  • Antineoplastic Agents
  • Bcl-2-Like Protein 11
  • HSP70 Heat-Shock Proteins